Top

Published in:

01-11-2011 | Pictorial Essay

Medication neurotoxicity in children

Authors: Ramesh S. Iyer, Apeksha Chaturvedi, Sumit Pruthi, Paritosh C. Khanna, Gisele E. Ishak

Published in: Pediatric Radiology | Issue 11/2011

Abstract

Medication neurotoxicity may have a variety of imaging manifestations in children. In this pictorial essay, we review the two most common brain injury patterns, posterior reversible encephalopathy syndrome (PRES) and acute toxic leukoencephalopathy (ATL). Proposed etiologies, salient features on neurological imaging, and methods for differentiating these entities and their implications will be discussed. Certain agents do not fall into these two broad patterns but instead characteristically involve central structures. We individually review several medications and their respective neurotoxic appearances including methotrexate, cyclosporine A, tacrolimus, metronidazole and vigabatrin. Diagnosis of medication neurotoxicity may be achieved by the combination of new-onset neurological deficits, recent initiation of a new therapy agent and distinctive findings on magnetic resonance imaging. Clinical and radiological improvement and/or resolution are frequently observed after the agent is discontinued.

Hinchey J, Chaves C, Appignani B et al (1996) A reversible posterior leukoencephalopathy syndrome. N Engl J Med 334:494–500PubMedCrossRef

Ugurel MS, Hayakawa M (2005) Implications of post-gadolinium MRI results in 13 cases with posterior reversible encephalopathy syndrome. Eur J Radiol 53:441–449PubMedCrossRef

Hefzy HM, Bartynski WS, Boardman JF et al (2009) Hemorrhage in posterior reversible encephalopathy syndrome: imaging and clinical features. AJNR 30:1371–1379PubMedCrossRef

Incecik F, Hergüner MO, Altunbasak S et al (2009) Evaluation of nine children with reversible posterior encephalopathy syndrome. Neurol India 57:475–478PubMedCrossRef

McKinney AM, Short J, Truwit CL et al (2007) Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. AJR 189:904–912PubMedCrossRef

Casey SO, Sampaio RC, Michel E et al (2000) Posterior reversible encephalopathy syndrome: utility of fluid attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions. AJNR 21:1199–1206PubMed

Casey SO, Truwit CL (2000) Pontine reversible edema: a newly recognized imaging variant of hypertensive encephalopathy? AJNR 21:243–245PubMed

Mukherjee P, McKinstry RC (2001) Reversible posterior leukoencephalopathy syndrome: evaluation with diffusion-tensor imaging. Radiology 219:756–765PubMed

Covarrubias DJ, Luetmer PH, Campeau NG (2002) Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR 23:1038–1048PubMed

10.

Schwartz RB, Feske SK, Polak JF et al (2000) Preeclampsia-eclampsia: clinical and neuroradiographic correlates and insights into the pathogenesis of hypertensive encephalopathy. Radiology 217:371–376PubMed

11.

Provenzale JM, Petrella JR, Cruz LC Jr et al (2001) Quantitative assessment of diffusion abnormalities in posterior reversible encephalopathy syndrome. AJNR 22:1455–1461PubMed

12.

Tamaki K, Sadoshima S, Baumbach GL et al (1984) Evidence that disruption of the blood-brain barrier precedes reduction in cerebral blood flow in hypertensive encephalopathy. Hypertension 6(2 Pt 2):I75–I81PubMed

13.

Trommer BL, Homer D, Mikhael MA (1988) Cerebral vasospasm and eclampsia. Stroke 19:326–329PubMedCrossRef

14.

Ito T, Sakai T, Inagawa S et al (1995) MR angiography of cerebral vasospasm in preeclampsia. AJNR 16:1344–1346PubMed

15.

McKinney AM, Kieffer SA, Paylor RT et al (2009) Acute toxic leukoencephalopathy: potential for reversibility clinically and on MRI with diffusion-weighted and FLAIR imaging. AJR 193:192–206PubMedCrossRef

16.

Beitinjaneh A, McKinney AM, Cao Q et al (2011) Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation. Biol Blood Marrow Transplant 17:300–308PubMedCrossRef

17.

Filley CM (1999) Toxic leukoencephalopathy. Clin Neuropharmacol 22:249–260PubMed

18.

Filley CM (2001) Toxic leukoencephalopathy. N Engl J Med 345:425–432PubMedCrossRef

19.

Sandoval C, Kutscher M, Jayabose S et al (2003) Neurotoxicity of intrathecal methotrexate: MR imaging findings. AJNR 24:1887–1890PubMed

20.

Rollins N, Winick N, Bash R et al (2004) Acute methotrexate neurotoxicity: findings on diffusion-weighted imaging and correlation with clinical outcome. AJNR 25:1688–1695PubMed

21.

Shibutani M, Okeda R (1989) Experimental study on subacute neurotoxicity of methotrexate in cats. Acta Neuropathol 78:291–300PubMedCrossRef

22.

Akiba T, Okeda R, Tajima T (1996) Metabolites of 5-fluorouracil, alpha-fluoro-beta-alanine and fluoroacetic acid, directly injure myelinated fibers in tissue culture. Acta Neuropathol 92:8–13PubMedCrossRef

23.

Okeda R, Shibutani M, Matsuo T et al (1990) Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetic acid and alpha-fluoro-beta-alanine. Acta Neuropathol 81:66–73PubMedCrossRef

24.

Fisher MJ, Khademian ZP, Simon EM et al (2005) Diffusion-weighted MR imaging of early methotrexate-related neurotoxicity in children. AJNR 26:1686–1689PubMed

25.

Chessels JM, Cox TC, Kendall B et al (1990) Neurotoxicity in lymphoblastic leukaemia: comparison of oral and intramuscular methotrexate and two doses of radiation. Arch Dis Child 65:416–422CrossRef

26.

Jaffe N, Takaue Y, Anzai T et al (1985) Transient neurologic disturbances induced by high-dose methotrexate treatment. Cancer 56:1356–1360PubMedCrossRef

27.

Gowan GM, Herrington JD, Simonetta AB (2002) Methotrexate induced toxic leukoencephalopathy. Pharmacotherapy 22:1183–1187PubMedCrossRef

28.

Matsumoto K, Takahashi S, Sato A et al (1995) Leukoencephalopathy in childhood hematopoietic neoplasm caused by moderate-dose methotrexate and prophylactic cranial radiotherapy: an MR analysis. Int J Radiat Oncol Biol Phys 32:913–918PubMedCrossRef

29.

Lien HH, Blomlie V, Saeter G et al (1991) Osteogenic sarcoma: MR signal abnormalities of the brain in asymptomatic patients treated with high-dose methotrexate. Radiology 179:547–550PubMed

30.

Rosencrantz R, Moon A, Raynes H et al (2001) Cyclosporine-induced neurotoxicity during treatment of Crohn’s disease: lack of correlation with previously reported risk factors. Am J Gastroenterol 92:2778–2782CrossRef

31.

Trullemans F, Grignard F, Van Camp B et al (2001) Clinical findings and magnetic resonance imaging in severe cyclosporine-related neurotoxicity after allogenic bone marrow transplantation. Eur J Haematol 67:94–99PubMedCrossRef

32.

Bartynski WS, Zeigler Z, Spearman MP et al (2001) Etiology of cortical and white matter lesions in cyclosporine-A and FK-506 neurotoxicity. AJNR 22:1901–1914PubMed

33.

Lucey MR, Kolars JC, Merion RM et al (1990) Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA. Lancet 335:11–15PubMedCrossRef

34.

Reece DE, Frei-Lahr DA, Shephard JD et al (1991) Neurologic complications in allogenic bone marrow transplant patients receiving cyclosporin. Bone Marrow Transplant 8:393–401PubMed

35.

Gijtenbeek JM, van den Bent MJ, Vecht CJ (1999) Cyclosporine neurotoxicity: a review. J Neurol 246:339–346PubMedCrossRef

36.

Schwartz RB, Bravo SM, Klufas RA et al (1995) Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases. AJR 165:627–631PubMed

37.

Appignani BA, Bhadelia RA, Blacklow SC et al (1996) Neuroimaging findings in patients on immunosuppressive therapy: experience with tacrolimus toxicity. AJR 166:683–688PubMed

38.

Lacaille F, Hertz-Pannier L, Nassogne MC (2004) Magnetic resonance imaging for the diagnosis of acute leukoencephalopathy in children treated with tacrolimus. Neuropediatrics 35:130–133PubMedCrossRef

39.

Ahn KF, Lee JW, Hahn ST et al (2003) Diffusion-weighted MRI and ADC mapping in FK506 neurotoxicity. Br J Radiol 76:916–919PubMedCrossRef

40.

Freeman CD, Klutman NE, Lamp KC (1997) Metronidazole: a therapeutic review and update. Drugs 54:679–708PubMedCrossRef

41.

Frytak S, Moertel CH, Childs DS (1978) Neurologic toxicity associated with high-dose metronidazole therapy. Ann Intern Med 88:361–362PubMed

42.

Kim E, Na DG, Kim EY et al (2007) MR imaging of metronidazole-induced encephalopathy: lesion distribution and diffusion-weighted imaging findings. AJNR 28:1652–1658PubMedCrossRef

43.

Heaney CJ, Campeau NG, Lindell EP (2003) MR imaging and diffusion-weighted imaging changes in metronidazole (Flagyl)-induced cerebellar toxicity. AJNR 24:1615–1617PubMed

44.

Ahmed A, Loes DJ, Bressler EL (1995) Reversible resonance imaging findings in metronidazole-induced encephalopathy. Neurology 45:588–589PubMed

45.

Cecil KM, Halsted MJ, Schapiro M et al (2002) Reversible MR imaging and MR spectroscopy abnormalities in association with metronidazole therapy. J Comput Assist Tomogr 26:948–951PubMedCrossRef

46.

McErlean A, Abdalia K, Donoghue V et al (2010) The dentate nucleus in children: normal development and patterns of disease. Pediatr Radiol 40:326–339PubMedCrossRef

47.

Pearl PL, Vezina LG, Saneto RP et al (2009) Cerebral MRI abnormalities associated with vigabatrin therapy. Epilepsia 50:184–194PubMedCrossRef

48.

Ben-Ari Y (2006) Basic developmental rules and their implications for epilepsy in the immature brain. Epileptic Disord 8:91–102PubMed

49.

Dracopoulos A, Widjaja E, Raybaud C et al (2010) Vigabatrin-associated reversible MRI signal changes in patients with infantile spasms. Epilepsia 51:1297–1304PubMedCrossRef

50.

Wheless JW, Carmant L, Bebin M et al (2009) Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy. Epilepsia 50:195–205PubMedCrossRef

51.

Thapa M, Khanna PC (2010) Vigabatrin-associated diffusion MRI abnormalities in tuberous sclerosis. Pediatr Radiol 48(Suppl 1):S153CrossRef

Title: Medication neurotoxicity in children
Authors: Ramesh S. Iyer
Apeksha Chaturvedi
Sumit Pruthi
Paritosh C. Khanna
Gisele E. Ishak
Publication date: 01-11-2011
Publisher: Springer-Verlag
Published in: Pediatric Radiology / Issue 11/2011
Print ISSN: 0301-0449
Electronic ISSN: 1432-1998
DOI: https://doi.org/10.1007/s00247-011-2191-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Medication neurotoxicity in children

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2011

Ultrasound and colour Doppler in infantile subglottic haemangioma

Interloop fluid in intussusception

Contrast-enhanced US (CEUS) in children: ready for prime time in the United States

Common and uncommon vascular rings and slings: a multi-modality review

Normal conus medullaris FDG uptake in children

Pleuropulmonary blastoma in a child with autosomal‐recessive polycystic kidney disease